Brief: Valneva Submits Adolescent Label Extension Application For Chikungunya Vaccine IXCHIQ® To UK MHRA
31/03/2025 06:04
March 31 (Reuters) - Valneva SE VLS.PA: VALNEVA SUBMITS ADOLESCENT LABEL EXTENSION APPLICATION FOR ITS CHIKUNGUNYA VACCINE, IXCHIQ®, TO UK MHRA Source text: ID:nGNX82L7pW Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency